PROMPT SEPSIS : Partnership for Rapid On-site Microfluidic POC Test for Sepsis ¬¬¬

PROMPT SEPSIS：针对脓毒症进行快速现场微流体 POC 测试的合作伙伴关系

• 批准号: 101192
• 金额: $ 20.39万
• 依托单位: MICROLAB DEVICES LIMITED
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=101192
• 关键词: PROMPT; SEPSIS; Partnership; Rapid; site

Sepsis, a severe illness in which the bloodstream is overwhelmed by bacteria, affects 18 million people worldwide annually. Symptoms can be non-specific so there are often delays in diagnosis. It is rapidly progressive illness which, if untreated can result in major organs and body systems not functioning and eventually, death. In the UK, sepsis affects up to 64,000 annually - more than breast, bowel and prostate cancers combined. Simple, timely interventions including antibiotics and intravenous fluids can halve the risk of death.Unfortunately, current sepsis tests are unreliable, especially if the onset is rapid. Tests routinely used require a blood sample to be taken and sent to the laboratory, whilst the clinician waits for the results to make a decision. PROMPT-SEPSIS proposes a low-cost, rapid point-of-care diagnostic platform using a finger prick or saliva sample to provide a rapid result to guide clinical decision-making, allowing a potentially lifesaving treatment to commence promptly.

脓毒症是一种严重的疾病，导致血液被细菌淹没，全球每年有1800万人受到影响。症状可能是非特异性的，因此诊断常常会延迟。这是一种进展迅速的疾病，如果不及时治疗，可能导致主要器官和身体系统功能丧失，最终导致死亡。在英国，败血症每年影响64000人，超过乳腺癌、肠癌和前列腺癌的总和。包括抗生素和静脉输液在内的简单、及时的干预措施可将死亡风险降低一半。不幸的是，目前的脓毒症测试是不可靠的，特别是如果发病迅速。常规检查需要采集血液样本并送到实验室，而临床医生则等待结果做出决定。PROMPT-SEPSIS提出了一种低成本、快速的即时诊断平台，使用手指刺破或唾液样本提供快速结果来指导临床决策，从而使可能挽救生命的治疗迅速开始。